![]() |
|
|
Vol. 288, Issue 2, 575-581, February 1999
Graduate School of Pharmaceutical Sciences, University of Tokyo,
Hongo, Bunkyo-ku, Tokyo, Japan (S.A., Y.K., Y.S.); and
Tsukuba Research
Institute, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba, Japan
(A.H.)
The biliary excretion mechanism of three derivatives of BQ-123, an
anionic cyclopentapeptide, was examined using isolated canalicular
membrane vesicles (CMVs) from Sprague-Dawley rats. The uptake by CMV of
BQ-485, a linear peptide, BQ-518, a cyclic peptide, and compound A, a
cyclic peptide with a cationic moiety, was stimulated by ATP. An
"overshoot" phenomenon and saturation were observed for the
ATP-dependent uptake of these three peptides. The Michaelis-Menten
constants (Km) for the uptake of BQ-485 and BQ-518 were comparable to the inhibition constants
(Ki) for their inhibitory effects on
ATP-dependent [3H]BQ-123 uptake. The uptake of BQ-485
showed the highest value and was inhibited by BQ-123 with a
Ki that was comparable to the Km for BQ-123 uptake. The ATP-dependent
uptake of BQ-123, BQ-485, and BQ-518 was much lower in CMVs from Eisai
hyperbilirubinemic rats, a strain having a hereditary defect of the
canalicular multispecific organic anion transporter (cMOAT). These
results suggest that both BQ-485 and BQ-518 principally share the cMOAT
transporter with BQ-123. Compound A almost completely inhibited BQ-123
uptake, although its ATP-dependent uptake was much lower than that of the other three peptides. The ATP-dependent uptake of compound A was
not very different in Sprague-Dawley rats and Eisai hyperbilirubinemic rats and was not inhibited by
S-(2,4-dinitrophenyl)-glutathione, a typical substrate
for cMOAT. Thus, although compound A inhibits cMOAT-mediated transport,
its own transport by cMOAT is minimal and mediated by another
transporter. This low degree of primary active transport by cMOAT may
be the principal reason for its relatively longer residence in the circulation.
This article has been cited by other articles:
![]() |
J. Madon, B. Hagenbuch, L. Landmann, P. J. Meier, and B. Stieger Transport Function and Hepatocellular Localization of mrp6 in Rat Liver Mol. Pharmacol., March 1, 2000; 57(3): 634 - 641. [Abstract] [Full Text] |
||||
![]() |
S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier, and Y. Sugiyama Carrier-Mediated Hepatic Uptake of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1107 - 1115. [Abstract] [Full Text] |
||||
![]() |
Y. Kato, S. Akhteruzzaman, A. Hisaka, and Y. Sugiyama Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 568 - 574. [Abstract] [Full Text] |
||||